Last edition
News about "Harbour BioMed"
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
Harbour BioMed | 23/03/2026 | By News Bureau
National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
Harbour BioMed | 10/03/2026 | By News Bureau
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Harbour BioMed | 19/01/2026 | By News Bureau | 144
Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.
Harbour BioMed | 30/12/2025 | By News Bureau
Harbour BioMed Advances Global Biotherapeutics Collaboration With AstraZeneca
The alliance focuses on discovering and developing next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, by combining the scientific strengths of both companies.
Harbour BioMed | 25/11/2025 | By Darshana | 146
Harbour BioMed, AstraZeneca Advance Next-Gen Oncology Biotherapeutics Collaboration
Harbour BioMed has announced an update on the advancement of its global strategic collaboration with AstraZeneca to discover and develop next-generation biotherapeutics in oncology, including antibody-drug conjugates (ADCs) and T cell engagers.
Harbour BioMed | 24/11/2025 | By Dineshwori | 198
Harbour BioMed and Evinova China Partner to Accelerate AI-Enabled Drug Development
Under the agreement, Harbour BioMed and Evinova China will combine their respective strengths to build an open ecosystem for AI-driven drug research and development.
Harbour BioMed | 07/11/2025 | By Dineshwori | 282
Harbour BioMed Names Yajie Li as Chief Medical Officer
As Chief Medical Officer (CMO), Yajie Li will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
Harbour BioMed | 25/08/2025 | By Dineshwori | 128
WuXi Vaccines, Harbour BioMed in partnership for manufacturing facility
The 8,500-square-metre facility includes multiple 250L, 500L and 1000L single-use bioreactors as well as sterile drug-product manufacturing lines
<br />
Harbour BioMed | 21/11/2022 | By Sudeep Soparkar | 835
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy